Nanosonics
ASX:NAN
Fresh from receiving FDA approval, the $1.3 billion medical device company is one of the stronger performers on the ASX this year. But short sellers sniff weakness.
Your complimentary access ends . To keep reading without interruption, subscribe today.
ASX:NAN
Fresh from receiving FDA approval, the $1.3 billion medical device company is one of the stronger performers on the ASX this year. But short sellers sniff weakness.
Your email address will be stored in accordance with our privacy policy.